Clinical Trials Logo

Clinical Trial Summary

This is an open, single-arm, investigator-initiated Phase I clinical trial to evaluate the safety, tolerability, and initial efficacy of BST02 injection in patients with locally advanced / metastatic liver cancer. This study includes a dose escalation study and a dose extension study, which will observe the effects of different IL-2 injection doses on the safety and efficacy of BST02. After signing the informed consent, the subjects will roughly go through two periods: the main study period and the long-term follow-up period. The main study period includes screening period, treatment and safety observation period, and follow-up period


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06173726
Study type Interventional
Source BioSyngen Pte Ltd
Contact
Status Not yet recruiting
Phase Early Phase 1
Start date December 5, 2023
Completion date December 5, 2026